schizophrenia

Apr 28 2025

Uncategorized

Cobenfy as an Adjunctive Agent in Schizophrenia: Peter J. Weiden, MD, Shares Insights on the Latest Findings – Psychiatric Times

by Clinical Editor

No Comments

Cobenfy as an Adjunctive Agent in Schizophrenia: Peter J. Weiden, MD, Shares Insights on the Latest Findings  Psychiatric Times

Apr 28 2025

Uncategorized

Neuroleptic Malignant Syndrome Following Brexpiprazole Initiation in a Treatment-Resistant Schizophrenia Patient With Influenza A: A Case Report – Cureus

by Clinical Editor

No Comments

Neuroleptic Malignant Syndrome Following Brexpiprazole Initiation in a Treatment-Resistant Schizophrenia Patient With Influenza A: A Case Report  Cureus

Apr 27 2025

Uncategorized

Bristol Myers’ Cobenfy fails in key study as add-on treatment for schizophrenia

by Clinical Editor

No Comments

By Sriparna Roy (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that would help expand...

Apr 27 2025

Uncategorized

Substance-Induced vs Primary Psychosis: Are They Different?

by Clinical Editor

No Comments

Are substance-induced psychosis and primary psychosis fundamentally different? And if they are, does it matter?

Apr 26 2025

Uncategorized

BMS shrugs off Cobenfy’s schizophrenia hit as it gears up for Alzheimer’s psychosis readout, 7 trial starts

by Clinical Editor

No Comments

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the...

Apr 26 2025

Uncategorized

Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan

by Clinical Editor

No Comments

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. | Schizophrenia drug...

Apr 25 2025

Uncategorized

Bristol Myers’ Cobenfy fails to meet main goal as add-on treatment for schizophrenia

by Clinical Editor

No Comments

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a late-stage trial studying it as an add-on treatment for schizophrenia, …

Apr 25 2025

Uncategorized

In the U.S., Schizophrenia Voices Are Angry—In India and Africa, They’re Supportive, Research Shows

by Clinical Editor

No Comments

Have you ever wondered why the same mental health condition can feel so different depending on where you live? How do cultural influences on schizophrenia hallucinations affect the way voices...

Apr 24 2025

Uncategorized

Eye scans may help detect risk for schizophrenia

by Clinical Editor

No Comments

A new study led by scientists from the University of Zurich and the University Hospital of Psychiatry Zurich has found a possible link between a person’s genetic risk for schizophrenia...

Apr 24 2025

Uncategorized

Ex-DGP Om Prakash’s wife Pallavi suffered from schizophrenia

by Clinical Editor

No Comments

Bengaluru: The murder of former Karnataka Police chief om Prakash, allegedly by his wife, has sent shockwaves across the state as chilling details about the intensity and magnitude of the